Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat in Metastatic Thyroid Carcinoma
NCT00134043Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 2005
- Primary completion
- Mar 2009
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of vorinostat in thyroid cancer, sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate at 3 years. Started Dec 2005; status: completed.
02
Drugs
vorinostat
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on NCT00134043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00134043.